Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2447540 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TSHRCES2CES1LMNA | |
| SCHEMBL2446211 | 0.85 | ALDH1A1 (0.43) | ALDH1A1TSHRCES2CES1LMNA | |
| SCHEMBL2448463 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRCES2CES1HDAC3 | |
| SCHEMBL2449188 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL2446501 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL2940393 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL2446633 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL2948731 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL2448546 | 0.84 | CES2 (0.45) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL11386864 | 0.83 | ALDH1A1 (0.42) | ALDH1A1TSHRCES2CES1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10551345-B2 | Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2020-02-04 | — | — | US | claimed |
| US-20170356877-A1 | POLY AND COPOLY(N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | APPLIED BIOSYSTEMS, LLC (US) | 2017-12-14 | — | — | US | claimed |
| US-9671367-B2 | Poly and copoly(N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2017-06-06 | — | — | US | claimed |
| US-20140209461-A1 | Poly and Copoly(N-vinylamide)s and Their Use In Capillary Electrophoresis | APPLIED BIOSYSTEMS, LLC (US) | 2014-07-31 | — | — | US | claimed |
| EP-2053067-B1 | Poly and copoly (N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS LLC (US) | 2011-09-14 | — | — | EP | claimed |
| CN-101724216-A | Poly and copolyn(N-vinylamide)s and their use in capillary electrophoresis | APPLIED BIOSYSTEMS | 2010-06-09 | — | — | CN | claimed |
| US-20100051461-A1 | Poly and Copolyn(N-Vinylamide)s and their use in Capillary Electrophoresis | Life Technologies Corporation (US) | 2010-03-04 | — | — | US | claimed |
| US-7641765-B2 | Applying slurry containing optical brighteners | BASF AKTIENGESELLSCHAFT (DE) | 2010-01-05 | — | — | US | claimed |
| CN-100567339-C | (N-vinylamide) polymers and copolymers and their use in capillary electrophoresis | APPLERA CORP (US) | 2009-12-09 | — | — | CN | claimed |
| EP-2053067-A1 | Poly and copoly (N-vinylamide)s and their use in capillary electrophoresis | Applied Biosystems Inc. (US) | 2009-04-29 | — | — | EP | claimed |
| EP-1636279-B1 | POLY AND COPOLY (N -VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | APPLIED BIOSYSTEMS (US) | 2009-02-18 | — | — | EP | claimed |
| CN-1816573-A | (N-vinylamide) polymers and copolymers and their use in capillary electrophoresis | APPLERA CORP (US) | 2006-08-09 | — | — | CN | claimed |
| EP-1636279-A1 | POLY AND COPOLY (N -VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | Applera Corporation (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050025741-A1 | Copolymers with (meth)acrylamides; improved separation of polynucleotides | APPLIED BIOSYSTEMS, LLC | 2005-02-03 | — | — | US | claimed |
| WO-2004104054-A1 | POLY AND COPOLY (N-VINYLAMIDE)S AND THEIR USE IN CAPILLARY ELECTROPHORESIS | APPLERA CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| CN-120025625-A | Foaming composition and application thereof, foaming material and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-117986814-A | Antibacterial biodegradable expanded beads, preparation method thereof, expanded bead molded body and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-0134921-A1 | Copolymer, process for its preparation and its use as a sorbent | CASSELLA Aktiengesellschaft (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0131179-A1 | Copolymer, process for its preparation and its use as a sorbent | CASSELLA Aktiengesellschaft (DE) | 1985-01-16 | — | — | EP | disclosed |
| US-4179292-A | Light-sensitive copying composition | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025741-A1 | Copolymers with (meth)acrylamides; improved separation of polynucleotides | POLI, PCNA, POLL | ALDH1A1 3357/4885TSHR 4259/4885CES2 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.